Equities

Avricore Health Inc

Avricore Health Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.19
  • Today's Change-0.005 / -2.56%
  • Shares traded176.95k
  • 1 Year change-7.32%
  • Beta-1.8086
Data delayed at least 15 minutes, as of Sep 20 2024 19:55 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Avricore Health Inc grew revenues 97.08% from 1.77m to 3.49m while net income improved from a loss of 818.23k to a smaller loss of 701.22k.
Gross margin36.16%
Net profit margin-0.07%
Operating margin0.15%
Return on assets-0.12%
Return on equity-0.14%
Return on investment-0.14%
More ▼

Cash flow in CADView more

In 2023, cash reserves at Avricore Health Inc fell by 343.96k. However, the company earned 660.40k from its operations for a Cash Flow Margin of 18.95%. In addition the company generated 42.50k cash from financing while 1.05m was spent on investing.
Cash flow per share0.0047
Price/Cash flow per share41.77
Book value per share0.0228
Tangible book value per share0.0222
More ▼

Balance sheet in CADView more

Avricore Health Inc uses little or no debt in its capital structure.
Current ratio2.79
Quick ratio2.76
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.